Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Source: SeekingAlpha
2025-12-08 14:46:32 ET
Since my article , "Regeneron: Strong R&D Pipeline Drives Growth Outlook," Regeneron Pharmaceuticals shares (NASDAQ: REGN ) have finally broken out of the accumulation phase, rising 27.4% to $718.4....
Read the full article on Seeking Alpha
For further details see:
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Sangamo Therapeutics Inc.
NASDAQ: SGMO
SGMO Trading
-1.45% G/L:
$0.4081 Last:
1,264,539 Volume:
$0.41 Open:
SGMO Latest News
March 09, 2026 08:05:00 am
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
February 03, 2026 04:05:00 pm
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium(TM) 2026
February 03, 2026 09:10:43 am
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
December 18, 2025 08:05:00 am
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
SGMO Stock Data
$133,083,570
322,698,215
1.31%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
Richmond
